Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Endocrine-Related Cancer|June 11, 2005
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trialA Bottini, A Berruti, M P Brizzi, et al.
Breast Cancer Research : BCR|February 5, 2011
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifenStephen B Fox, Daniele Generali, Alfredo Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patientsA Bottini, A Berruti, A Bersiga, et al.
BMC Cancer|November 6, 2009
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology networkMaria P Brizzi, Alfredo Berruti, Anna Ferrero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2005
Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokersS Novello, C Fava, P Borasio, et al.
International Journal of Oncology|July 17, 1998
Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patientsA Bottini, A Berruti, A Bersiga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancerDaniele Generali, Alfredo Berruti, Maria P Brizzi, et al.
Endocrine-Related Cancer|September 7, 2006
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancerDaniele Generali, Stephen B Fox, Alfredo Berruti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancerDaniele Generali, Francesca M Buffa, Alfredo Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patientsDaniele Generali, Gaynor Bates, Alfredo Berruti, et al.
Pageof 4